# A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

> **NCT05148195** · PHASE2 · TERMINATED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 86 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Envofolimab
- **DRUG:** BD0801
- **DRUG:** Docetaxel
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin calcium
- **DRUG:** 5-Fluorouridine

## Key facts

- **NCT ID:** NCT05148195
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-22
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 86 (ACTUAL)
- **Why stopped:** The study was terminated due to the sponsor's research and development strategy adjustment.
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05148195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05148195, "A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05148195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*